Tyme Technologies Inc has a Bullish sentiment reading. If you require advice in relation to any financial matter you should consult an appropriate professional. Tyme Technologies Inc stock has gained 5.10 over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. Quote Chart Stock Analysis News Price vs Fair Value Sustainability Trailing Returns. Nothing on this website constitutes, or is meant to constitute, advice of any kind. Tyme Technologies Inc - Stock Chart TYME Morningstar Rating Rating as of Jun 16, 2022. Fintel makes no representations or warranties in relation to this website or the information and materials provided on this website. In that particular session, Stock kicked-off at the price of 0.2624 while reaching the peak value of 0.305 and lowest value recorded on the day was 0.2536.
(TYME) By Sarah Baker JAt the end of the latest market close, Tyme Technologies Inc. This website is provided “as is” without any representations or warranties, express or implied. The clock is ticking: Tyme Technologies Inc. See also AMC Short Interest, GME Short Interest, Scion Asset Management, Vanguard Group, Point72, Sabby,īaker Brothers, Citadel Advisors, Himalaya Capital, Baillie Gifford, See our Privacy Policy and Terms and Conditions. Information includes fund holdings, fund sentiment, financial data, and regulatory filings (including SEC, LSE, ASX, and SGX). The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.Fintel® provides advanced research tools for data-driven investorsįintel currently tracks over 9500 funds and over 63,000 securities traded worldwide. The company was formerly known as Global Group Enterprises Corp. (TYME)’s stock with other industry players reveals that stock’s current price change of 6.73 and that of -81.94 over the past 12 months is in competing position with that of Applied Genetic Technologies Corporation (AGTC) which saw its stock price fall by -1.15 in the last trading and went through a decrease of -78. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment NYU School of Medicine to examine multiple aspects of SM-88 mechanisms and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company also offers TYME-19, an oral synthetically produced member of the bile acid family, which is in preclinical stage for the treatment of COVID-19 and disease variants and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors.
Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing.
Company profile Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Institutional investors purchased a net 488.7 thousand shares of TYME during the quarter ended March 2019. BEDMINSTER, N.J.- ( BUSINESS WIRE )-TYME Technologies, Inc. NEW YORK, NY / ACCESSWIRE / Febru/ Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Tyme Technologies, Inc.('Tyme' or the 'Company'). These treatments are designed to work across a wide range of diagnoses, solid. SPXS Direxion Daily S&P 500 Bear 3X Shares TYME Technologies is a new biotechnology company that develops cancer metabolism-based therapies or CMBTs.
SPXL Direxion Daily S&P500 Bull 3X Shares TECL Direxion Daily Technology Bull 3X Shares UVXY ProShares Ultra VIX Short-Term Futures ETF SOXL Direxion Daily Semiconductor Bull 3X Shares